In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.Topics include:Currently approved ICIsRole of biomarker and PD-L1 testing in advanced NSCLCStrategies to individualize ICI treatment for patients with advanced NSCLCStrategies for identifying and managing immune-related adverse events in patients treated with ICIPresenter:Sandip P. Patel, MDAssociate ProfessorDepartment of MedicineDivision of Hematology/OncologyUniversity of California – San DiegoLa Jolla, California Link to full program:https://bit.ly/39vuCHC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ver todos los episodios